Ken Griffin Aquestive Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$2.31 - $4.5 $64,449 - $125,550	27,900 Added 83.28%	61,400 $159,000
Q1 2024 May 15, 2024	BUY	$2.01 - $6.09 $34,370 - $104,139	17,100 Added 104.27%	33,500 $142,000
Q4 2023 Feb 14, 2024	SELL	$1.29 - $2.47 $2,967 - $5,681	-2,300 Reduced 12.3%	16,400 $33,000
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.24 $15,300 - $22,848	10,200 Added 120.0%	18,700 $28,000
Q2 2023 Aug 14, 2023	SELL	$1.06 - $2.49 $9,646 - $22,659	-9,100 Reduced 51.7%	8,500 $14,000
Q1 2023 May 15, 2023	SELL	$0.72 - $1.15 $23,472 - $37,490	-32,600 Reduced 64.94%	17,600 $20,000
Q4 2022 Feb 14, 2023	BUY	$0.77 - $1.18 $38,654 - $59,236	50,200 New	50,200 $45,000

104

43.1M

271K

212K

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $273M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.